After suffering a setback in its joint venture with Sanofi, GlaxoSmithKline has been dropped by another vaccine partner, Clover, as it looks for the best adjuvant for its COVID-19 candidate.
Clover Biopharmaceuticals has pulled the plug on its partnership with GlaxoSmithKline to develop a COVID-19 vaccine using the UK giant's adjuvant, plumping instead to go into late-stage trials with an adjuvant from Dynavax Technologies Corporation of the US.
China-headquartered Clover had been evaluating its protein-based S-Trimer COVID-19 vaccine in a Phase I trial with two adjuvant, one from...
Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.
The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.
The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
